Company / Capital Returned to Shareholders
Kiniksa Pharmaceuticals International, plc Capital Returned to Shareholders History
FY2017-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
-
FY2018
5-year range
-
FY2017-FY2018
Trend
-
vs FY2017
Sector context
#47 of 52
Health Care
What the data says
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 52
▼
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $0 | - |
| FY2017 | $0 | - |
As of FY2018 · SEC 10-K · Updated Jun 30, 2026